Classes
DEA Class; Rx
Common Brand Names; Uloric
- Xanthine Oxidase Inhibitors;
- Antigout Agents
Description
Oral, non-purine selective xanthine oxidase inhibitor (XOI)
Used for the chronic management of gout, usually in patients with inadequate response or who are not candidates for allopurinol treatment
Carries a boxed warning for a potential increase in cardiovascular death vs. allopurinol
Indications
Indicated for chronic management of hyperuricemia in patients who:
- Responded inadequately to optimal allopurinol therapy
- Are intolerant to allopurinol
- Treatment with allopurinol not advisable
Contraindications
Coadministration with azathioprine or mercaptopurine
Adverse Effects
Liver function abnormalities (4.6-6.6%)
Rash (0.5-1.6%)
Nausea (1.1-1.3%)
Arthralgia (0.7-1.1%)
Blood and lymphatic system disorders: Anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia
Cardiac disorders: Angina pectoris, atrial fibrillation/flutter, cardiac murmur, ECG abnormal, palpitations, sinus bradycardia, tachycardia
Ear and labyrinth disorders: Deafness, tinnitus, vertigo
Eye disorders: Vision blurred
Gastrointestinal disorders: Abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, hematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting
General disorders and administration site conditions: Asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst
Hepatobiliary disorders: Cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly
Immune system disorder: Hypersensitivity
Infections and infestations: Herpes zoster
Procedural complications: Contusion
Warnings
After initiation, an increase in gout flares is frequently observed; increase is due to reduction in serum uric acid levels, resulting in mobilization of urate from tissue deposits
Not tested for secondary hyperuricemia; not recommended in patients whose rate of urate formation is greatly increased (eg, malignant disease and its treatment, Lesch-Nyhan syndrome)
Postmarketing reports of serious skin and hypersensitivity reactions reported; discontinue if serious skin reactions are suspected; caution in patients who reported previous similar skin reactions to allopurinol
Postmarketing reports of fatal and nonfatal hepatic failure; may increase liver enzyme activity; obtain LFTs at baseline, and do not initiate if alanine aminotransferase is 3x ULN with total bilirubin >2x ULN
Serious skin and hypersensitivity reactions, including Stevens-Johnson Syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) and toxic epidermal necrolysis (TEN) reported; discontinue therapy if serious skin reactions suspected; many patients reported previous similar skin reactions to allopurinol; use caution in these patients
Pregnancy and Lactation
Limited available data in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes
There are no data on presence of febuxostat in human milk, effects on breastfed infant, or on milk production
Maximum Dosage
Doses of up to 120 mg/day PO have been used in clinical trials.
Doses of up to 120 mg/day PO have been used in clinical trials.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
febuxostat
tablet
- 40mg
- 80mg